Table 1.
TRIPOD adherence reporting items
| Reporting Items | Applicable to study type | Reporting items for TRIPOD adherence |
||
|---|---|---|---|---|
| Development only | Development with validation | |||
| 1. Title | D,V | ✓ | ✓ | |
| 2. Abstract | D,V | ✓ | ✓ | |
| Introduction | ||||
| 3. Background and objectives | a. Context and rationale | D,V | ✓ | ✓ |
| b. Objectives | D,V | ✓ | ✓ | |
| Methods | ||||
| 4. Source of data | a. Study design or source of data | D,V | ✓ | ✓ |
| b. Key dates | D,V | ✓ | ✓ | |
| 5. Participants | a. Study setting (including number and location of centres) | D,V | ✓ | ✓ |
| b. Eligibility criteria | D,V | ✓ | ✓ | |
| c. Details of treatment, if relevant | D,V | (✓) | (✓) | |
| 6. Outcome | a. Outcome definition (including how and when assessed) | D,V | ✓ | ✓ |
| b. Blinding of outcome assessment | D,V | ✓ | ✓ | |
| 7. Predictors | a. Predictor definition (including how and when assessed) | D,V | ✓ | ✓ |
| b. Blinding of predictor assessment | D,V | ✓ | ✓ | |
| 8. Sample size | Arrival at study size | D,V | ✓ | ✓ |
| 9. Missing Data | Handling of missing data | D,V | ✓ | ✓ |
| 10. Statistical analysis | a. Handling of predictors in the analysis | D | ✓ | ✓ |
| b. Specification of the model, all model building procedures, and internal validation methods | D | ✓ | ✓ | |
| c. For validation, description of how predictions were made | V | ✗ | ✓ | |
| d. Specification of all measures used to assess model performance | D,V | ✓ | ✓ | |
| e. If done, description of model updating arising from validation | V | ✗ | (✓) | |
| 11. Risk groups | If done, details of how risk groups were created | D,V | (✓) | (✓) |
| 12. Development vs. validation | For validation, description of differences between development and validation data | V | ✗ | ✓ |
| Results | ||||
| 13. Participants | a. Description of flow of participants through the study | D,V | ✓ | ✓ |
| b. Description of characteristics of participants | D,V | ✓ | ✓ | |
| c. For validation, comparison with development data | V | ✗ | ✓ | |
| 14. Model development | a. Number of participants and outcome in each analysis | D | ✓ | ✓ |
| b. If done, unadjusted association between each candidate predictor and outcome | D | (✓) | (✓) | |
| 15. Model specification | a. Presentation of full prediction model | D | ✓ | ✓ |
| b. Explanation of how to use the prediction model | D | ✓ | ✓ | |
| 16. Model performance | Report of model performance measures | D,V | ✓ | ✓ |
| 17. Model updating | If done, report of results from any model updating | V | ✗ | (✓) |
| Discussion | ||||
| 18. Limitations | Limitations | D,V | ✓ | ✓ |
| 19. Interpretation | a. For validation, interpretation of performance measure results | V | ✗ | ✓ |
| b. Overall interpretation of results | D,V | ✓ | ✓ | |
| 20. Implications | Potential clinical use of the model and implications for future research | D,V | ✓ | ✓ |
| Other information | ||||
| 21. Supplementary* | Availability of supplementary resources | D,V | ✗ | ✗ |
| 22. Funding | Source of funding and role of funders | D,V | ✓ | ✓ |
| Total number of applicable items for TRIPOD adherence score | 30 | 36 | ||
D=development; V=validation
Parentheses () indicate conditional reporting items
⁎
21. Supplementary is not used to calculate TRIPOD adherence score